Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q1 FY22 results · Apr–Jun 2021
Natco Pharma reported revenue from operations of ₹410.30 crore (down 27.2% from Q1 FY21) and net profit of ₹75.00 crore (down 38.6% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 410.30 | 563.40 | −27.2% | 331.30 | +23.8% |
| Other income | 17.00 | 18.70 | −9.1% | 28.40 | −40.1% |
| Total income | 427.30 | 582.10 | −26.6% | 359.70 | +18.8% |
| Profit before tax | 91.00 | 158.10 | −42.4% | 70.70 | +28.7% |
| Net profit for the period | 75.00 | 122.10 | −38.6% | 53.00 | +41.5% |
| EPS, basic (₹) | 4.11 | 6.74 | −39.0% | 2.91 | +41.2% |
| Net margin (%) | 18.3 | 21.7 | 16.0 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 393.80 | 532.20 | −26.0% | 311.50 | +26.4% |
| Other income | 12.30 | 19.90 | −38.2% | 29.10 | −57.7% |
| Total income | 406.10 | 552.10 | −26.4% | 340.60 | +19.2% |
| Profit before tax | 91.00 | 161.60 | −43.7% | 73.40 | +24.0% |
| Net profit for the period | 75.20 | 126.70 | −40.6% | 57.20 | +31.5% |
| EPS, basic (₹) | 4.12 | 6.96 | −40.8% | 3.14 | +31.2% |
| Net margin (%) | 19.1 | 23.8 | 18.4 |
Consolidated
- Filed with BSE
- 12 Aug 2021, 17:34 IST
- Board meeting
- 12 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2021, 17:34 IST
- Board meeting
- 12 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE